SERUM MATRIX METALLOPROTEINASES AND THEIR TYPE I TISSUE INHIBITOR: СORELATION WITH LONG-TERM TREATMENT RESULTS OF BONE SARCOMAS PATIENTS

Issue: 
9
Year: 
2016

I.V. Babkina
Dr.Sc. (Med.), Professor, N.N. Blokhin Russian Cancer Research Center (Moscow)
E-mail: docbabkina@rambler.ru
I.S. Chernomaz
Post-graduate Student, A.I. Evdokimov Moscow State University of Medicine and Dentistry
A.V. Bondarev
Orthopedic Surgeon, Moscow Municipal Oncologic Hospital № 62
M.Yu. Schupack
Head of Orthopaedic Department, Orthopedic Surgeon, Moscow Municipal Oncologic Hospital № 62
Yu.N. Soloviev
Academician RAS, Leading Research Scientist, Pathology Department, N.N.Blokhin Russian Cancer Research Center (Moscow)
A.N. Makhson
Dr.Sc. (Med.), Chief Surgeon, Moscow Municipal Oncologic Hospital № 62
N.E. Kushlinskii
Dr.Sc. (Med.), Professor, Member-Correspondent of Russian Academy of Sciences,
A.I. Evdokimov Moscow State University of Medicine and Dentistry

Background: bone sarcomas belong to malignant tumors due to development hematogenous metastasis. Tumors markers expression study is impotent to detection new potential chemotherapy targets and evaluation disease prognosis. Aim of the study: a comparative study of the content of metalloproteinases - MMP-2, -7, -9 and tissue inhibitor TIMP-1 in the serum of patients with primary malignant bone tumors and healthy people to identify relationship with the tumor histological structure and the disease prognosis. Materials and methods: a comparative study of the content of metalloproteinases-2, -7, -9 and their inhibitor TIMP-1were performed in the serum of 54 patients with primary bone tumors (malignant - 45: central osteosarcoma 21, periosteal osteosarcoma - 4, Ewing's sarcoma - 11, primary chondrosarcoma - 6, undifferentiated pleomorphic sarcoma - 3 and borderline giant cell tumors - 9 and healthy individuals - 26 was conducted using «Biosource» USA for TIMP-1 and «RαD» USA for MMP-2, -7 and -9. Results: TIMP-1 levels in the serum of patients with central osteosarcoma and periosteal osteosarcoma was significantly higher, then in the serum of healthy persons. A direct correlation of TIMP-1 and MMP-9 was evaluated in the serum of patients with central osteosarcoma, periosteal sarcoma and Ewing's sarcoma. Significant differences in 5 year survival rate and levels of serum TIMP-1, MMP-2, -7, - 9 were not evaluated. But, 5-year survival rate with the level of MMP-2 >160 ng/ml in the serum was 1,6 times higher, then if the levels of MMP-2 were lower. If the levels of ММP-9 were 377 ng/ml. Minimal 5-year survival rates (33%) were evaluated in the serum of patients with ММP-2 377 ng/ml. Conclusion: the expression of MMP-2, MMP-9 and TIMP-1 can be linked to pathogenetic changes associated with the growth and metastatic sarcomas of bone and, in particular, osteosarcoma, and may be the subject of further studies to determine the levels of these indicators and their value in prognosis.

Keywords: 
Key words: TIMP-1
MMP-2
-7
-9
osteosarcoma
chondrosarcoma
Ewing sarcoma.